|

LHRH agonist Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Goserelin, Leuprolide, Triptorelin

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Rana McKay, MD1
  • Hoffmann-La Roche1
  • Fudan University1

Indications

  • Cancer3
  • Breast Cancer2
  • Prostatic Adenocarcinoma1
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer1
  • High-Risk Cancer1

Other1 trial

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

La Jolla, California1 trial

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

University of California San Diego - Moores Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.